Targeting anti-HIV drugs to the CNS

Expert Opinion on Drug Delivery

Volumn 6, Issue 8, 2009, Pages 771-784

  Rao, Kavitha S ^a   Ghorpade, Anuja ^a,b   Labhasetwar, Vinod ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NORTH TEXAS   (United States)

Author keywords

AIDS; Anti HIV drugs; BBB; CNS; Macrophage; Nanocarrier systems; Viral reservoirs

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DENDRIMER; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; ENFUVIRTIDE; ETRAVIRINE; FOSCARNET; INDINAVIR; LAMIVUDINE; LIPOSOME; LOPINAVIR; MARAVIROC; METHOTREXATE; NANOCARRIER; NANOPARTICLE; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TIPRANAVIR; TUBOCURARINE CHLORIDE; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

AREA UNDER THE CURVE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG MECHANISM; DRUG TARGETING; GENE THERAPY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONG TERM CARE; MICELLE; NERVE DEGENERATION; NONHUMAN; REVIEW; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; BLOOD-BRAIN BARRIER; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GENE THERAPY; HIV INFECTIONS; HIV-1; HUMANS; NANOPARTICLES; PEPTIDES;

EID: 68149171726     PISSN: 17425247     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425240903081705     Document Type: Review

References (105)

1. HIV/AIDS Statistics and Surveillance. CDC, 2006. Available from: http://www.cdc.gov/hiv/topics/surveillance/basic.htm#ddaids
2. AIDS Epidemic Update. UNAIDS, 2007. Available from: http://data.unaids. org/pub/EPISlides/2007/2007-epiupdate-en.pdf
3. Lange CG, Lederman MM, Medvik K, et al. Nadir CD4+ T-cell count and numbers of CD28+ CD4+ T-cells predict functional responses to immunizations in chronic HIV-1 infection. AIDS 2003;17:2015-2023 (Pubitemid 37297149)
4. Fleury S, de Boer RJ, Rizzardi GP, et al. Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med 1998;4:794-801 (Pubitemid 28331020)
5. Sachsenberg N, Perelson AS, Yerly S, et al. Turnover of CD4+ and CD8+ T lymphocytes in HIV-1 infection as measured by Ki-67 antigen. J Exp Med 1998;187:1295-1303 (Pubitemid 28189118)
6. Paparizos VA, Kyriakis KP, Kourkounti S, et al. The Influence of a HAART regimen on the expression of HIV-associated Kaposi sarcoma. J Acquir Immune Defic Syndr 2008;49:111 Letter United States
7. Kaul M. HIV's double strike at the brain: neuronal toxicity and compromised neurogenesis. Front Biosci 2008;13:2484-2494 (Pubitemid 351599699)
8. Folks T, Kelly J, Benn S, et al. Susceptibility of normal human lymphocytes to infection with HTLV-III/LAV. J Immunol 1986;136:4049-4053 (Pubitemid 16123049)
9. Nottet HS, Persidsky Y, Sasseville VG, et al. Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996;156:1284-1295 (Pubitemid 26048128)
10. An SF, Groves M, Giometto B, et al. Detection and localisation of HIV-1 DNA and RNA in fixed adult AIDS brain by polymerase chain reaction/in situ hybridisation technique. Acta Neuropathol 1999;98:481-487
11. Bagasra O, Lavi E, Bobroski L, et al. Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. Aids 1996;10:573-585 (Pubitemid 26162985)
12. Wiley CA, Achim CL, Christopherson C, et al. HIV mediates a productive infection of the brain. Aids 1999;13:2055-2059 (Pubitemid 29509581)
13. Canto-Nogues C, Sanchez-Ramon S, Alvarez S, et al. HIV-1 infection of neurons might account for progressive HIV-1-associated encephalopathy in children. J Mol Neurosci 2005;27:79-89 (Pubitemid 41112380)
14. Gorry PR, Ong C, Thorpe J, et al. Astrocyte infection by HIV-1: mechanisms of restricted virus replication, and role in the pathogenesis of HIV-1-associated dementia. Curr HIV Res 2003;1:463-473
15. Brack-Werner R. Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. Aids 1999;13:1-22
16. Wiley CA, Schrier RD, Nelson JA, et al. Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci USA 1986;83:7089-7093 (Pubitemid 16002375)
17. Grant I. Neurocognitive disturbances in HIV. Int Rev Psychiatry 2008;20:33-47
18. Letendre S, McCutchan JA, Ellis RJ. Neurologic complications of HIV disease and their treatment. Top HIV Med 2008;16:15-22
19. Ances BM, Ellis RJ. Dementia and neurocognitive disorders due to HIV-1 infection. Semin Neurol 2007;27:86-92 • Review article focusing on neurocognitive impairments associated with HIV infection of the CNS.
20. Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007;69:1789-1799 (Pubitemid 350059308)
21. Hinkin CH, Castellon SA, Atkinson JH, et al. Neuropsychiatric aspects of HIV infection among older adults. J Clin Epidemiol 2001;54(Suppl 1):S44-52
22. Wiseman MB, Sanchez JA, Buechel C, et al. Patterns of relative cerebral blood flow in minor cognitive motor disorder in human immunodeficiency virus infection. J Neuropsychiatry Clin Neurosci 1999;11:222-233 (Pubitemid 29224849)
23. Sevigny JJ, Albert SM, McDermott MP, et al. Evaluation of HIV RNA and markers of immune activation as predictors of HIV-associated dementia. Neurology 2004;63:2084-2090
24. Maschke M, Kastrup O, Esser S, et al. Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active antiretroviral therapy (HAART). J Neurol Neurosurg Psychiatry 2000;69:376-380 (Pubitemid 30636242)
25. Nath A. Human immunodeficiency virus (HIV) proteins in neuropathogenesis of HIV dementia. J Infect Dis 2002;186(Suppl 2):S193-8 (Pubitemid 35370481)
26. Rao KS, Reddy MK, Horning JL, et al. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008;29:4429-4438
27. Stewart SA, Poon B, Song JY, et al. Human immunodeficiency virus type 1 vpr induces apoptosis through caspase activation. J Virol 2000;74:3105-3111 (Pubitemid 30143733)
28. Corasaniti MT, Strongoli MC, Piccirilli S, et al. Apoptosis induced by gp120 in the neocortex of rat involves enhanced expression of cyclooxygenase type 2 and is prevented by NMDA receptor antagonists and by the 21-aminosteroid U-74389G. Biochem Biophys Res Commun 2000;274:664-669 (Pubitemid 30663677)
29. Alirezaei M, Watry DD, Flynn CF, et al. Human immunodeficiency virus-1/surface glycoprotein 120 induces apoptosis through RNA-activated protein kinase signaling in neurons. J Neurosci 2007;27:11047-11055 (Pubitemid 47574170)
30. Ghafouri M, Amini S, Khalili K, et al. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006;3:28 • Review article describing the neuropathology of HIV infection. (Pubitemid 47202076)
31. Cook JE, Dasgupta S, Middaugh LD, et al. Highly active antiretroviral therapy and human immunodeficiency virus encephalitis. Ann Neurol 2005;57:795-803 (Pubitemid 40798617)
32. Boisse L, Gill MJ, Power C. HIV infection of the central nervous system: clinical features and neuropathogenesis. Neurol Clin 2008;26:799-819 (Pubitemid 352037443)
33. Tozzi V, Balestra P, Bellagamba R, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. J Acquir Immune Defic Syndr 2007;45:174-182 (Pubitemid 46869810)
34. Robinson-Papp J, Byrd D, Mindt MR, et al. Motor function and human immunodeficiency virus-associated cognitive impairment in a highly active antiretroviral therapy-era cohort. Arch Neurol 2008;65:1096-1101 • An important clinical study describing the predictors of cognitive impairments in patients on antiretroviral therapy.
35. Rumbaugh JA, Nath A. Developments in HIV neuropathogenesis. Curr Pharm Des 2006;12:1023-1044
36. Clifford DB. HIV-associated neurocognitive disease continues in the antiretroviral era. Top HIV Med 2008;16:94-98
37. Tan H, Rader AJ. Identification of putative, stable binding regions through flexibility analysis of HIV-1 gp120. Proteins 2008;74:881-894
38. Kwei GY, Novak LB, Hettrick LA, et al. Regiospecific intestinal absorption of the HIV protease inhibitor L-735,524 in beagle dogs. Pharm Res 1995;12:884-888
39. Lin JH, Chen IW, Vastag KJ, et al. pH-dependent oral absorption of L-735,524, a potent HIV protease inhibitor, in rats and dogs. Drug Metab Dispos 1995;23:730-735
40. Bocedi A, Notaril S, Narciso P, et al. Binding of anti-HIV drugs to human serum albumin. IUBMB Life 2004;56(10):609-614 (Pubitemid 40385357)
41. Greene JN, Poblete SJ, Krieff D. New directions in antimicrobial therapy. Chest Surg Clin N Am 1999;9:39-61, vii-viii
42. Markowitz M, Mohri H, Mehandru S, et al. Infection with multidrug resistant, dual-tropic HIV-1 and rapid progression to AIDS: a case report. Lancet 2005;365:1031-1038 (Pubitemid 40386780)
43. Ho D. Residual pool of HIV after prolonged combination therapy. 5th Conference on Retroviruses and Opportunistic Infections; Chicago, IL; February 3 1998
44. Ho DD. Therapy of HIV infections: problems and prospects. Bull NY Acad Med 1996;73:37-45 •• Review discussing the limitations of currently existing antiretroviral therapy.
45. Crowe SM, McGrath MS, Elbeik T, et al. Comparative assessment of antiretrovirals in human monocyte-macrophages and lymphoid cell lines acutely and chronically infected with the human immunodeficiency virus. J Med Virol 1989;29:176-180 (Pubitemid 20006346)
46. Brightman MW, Reese TS. Junctions between intimately apposed cell membranes in the vertebrate brain. J Cell Biol 1969;40:648-677
47. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci 1999;22:11-28
48. Crone C, Christensen O. Electrical resistance of a capillary endothelium. J Gen Physiol 1981;77:349-371
49. Chaudhuri JD. Blood brain barrier and infection. Med Sci Monit 2000;6:1213-1222 • Review examining the different mechanisms by which HIV infects the brain.
50. Takasawa K, Terasaki T, Suzuki H, et al. In vivo evidence for carrier-mediated efflux transport of 3′-azido-3′-deoxythymidine and 2′,3′-dideoxyinosine across the blood-brain barrier via a probenecid-sensitive transport system. J Pharmacol Exp Ther 1997;281:369-375
51. Wang Y, Sawchuk RJ. Zidovudine transport in the rabbit brain during intravenous and intracerebroventricular infusion. J Pharm Sci 1995;84:871-876
52. Tsuji A. Small molecular drug transfer across the blood-brain barrier via carrier-mediated transport systems. NeuroRx 2005;2:54-62 (Pubitemid 40128026)
53. Schinkel AH. The roles of P-glycoprotein and MRP1 in the blood-brain and blood-cerebrospinal fluid barriers. Adv Exp Med Biol 2001;500:365-372
54. Thiebaut F, Tsuruo T, Hamada H, et al. Immunohistochemical localization in normal tissues of different epitopes in the multidrug transport protein P170: evidence for localization in brain capillaries and crossreactivity of one antibody with a muscle protein. J Histochem Cytochem 1989;37:159-164 (Pubitemid 19039163)
55. Dwibhashyam VSNM, Nagappa A. Strategies for enhanced drug delivery to the central nervous system. Indian J Pharm Sci 2008;70:145-153 (Pubitemid 351920187)
56. Prokai-Tatrai K, Prokai L, Bodor N. Brain-targeted delivery of a leucine-enkephalin analogue by retrometabolic design. J Med Chem 1996;39:4775-4782 (Pubitemid 26423897)
57. Ikeda M, Bhattacharjee AK, Kondoh T, et al. Synergistic effect of cold mannitol and Na(+)/Ca(2+) exchange blocker on blood-brain barrier opening. Biochem Biophys Res Commun 2002;291:669-674
58. Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 1984;15:362-366
59. Salahuddin TS, Johansson BB, Kalimo H, et al. Structural changes in the rat brain after carotid infusions of hyperosmolar solutions: a light microscopic and immunohistochemical study. Neuropathol Appl Neurobiol 1988;14:467-482 (Pubitemid 19025369)
60. Hynynen K. Focused ultrasound for bloodâ "brain disruption and delivery of therapeutic molecules into the brain. Expert Opinion on Drug Deliv 2007;4:27-35
61. Oztas B, Kucuk M. Intracarotid hypothermic saline infusion: a new method for reversible blood-brain barrier disruption in anesthetized rats. Neurosci Lett 1995;190:203-206
62. Spigelman MK, Zappulla RA, Johnson J, et al. Etoposide-induced blood-brain barrier disruption. J Neurosurg 1984;61:674-678
63. Zhang Y, Schlachetzki F, Pardridge WM. Global non-viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003;7:11-18 (Pubitemid 36305354)
64. Pardridge WM. Brain drug targeting: the future of brain drug development. Cambridge, U.K.: Cambridge University Press, 2003 • Book discussing the strategies for targeted delivery of drugs to the CNS.
65. Coloma MJ, Lee HJ, Kurihara A, et al. Transport across the primate blood-brain barrier of a genetically engineered chimeric monoclonal antibody to the human insulin receptor. Pharm Res 2000;17:266-274 (Pubitemid 30225129)
66. Pardridge WM. Molecular Trojan horses for blood-brain barrier drug delivery. Curr Opin Pharmacol 2006;6:494-500 • This paper discusses the application of genetically engineered peptides as molecular Trojan horses for brain drug delivery.
67. Tiwari SB, Amiji MM. A review of nanocarrier-based CNS delivery systems. Curr Drug Deliv 2006;3:219-232
68. Schnyder A, Huwyler J. Drug transport to brain with targeted liposomes. NeuroRx 2005;2:99-107 (Pubitemid 40128030)
69. Dusserre N, Lessard C, Paquette N, et al. Encapsulation of foscarnet in liposomes modifies drug intracellular accumulation, in vitro anti-HIV-1 activity, tissue distribution and pharmacokinetics. AIDS 1995;9:833-841
70. Reddy MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J 2009;23:1384-1395
71. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005;4:145-160 • A comprehensive review on liposomal brain drug delivery.
72. Dhanikula RS, Argaw A, Bouchard JF, et al. Methotrexate loaded polyether-copolyester dendrimers for the treatment of gliomas: enhanced efficacy and intratumoral transport capability. Mol Pharm 2008;5:105-116 (Pubitemid 351300040)
73. Huang RQ, Qu YH, Ke WL, et al. Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. FASEB J 2007;21:1117-1125
74. Dutta T, Jain NK. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007;1770:681-686 (Pubitemid 46281473)
75. Wolinsky JB, Grinstaff MW. Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev 2008;60:1037-1055
76. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54:759-779
77. Spitzenberger TJ, Heilman D, Diekmann C, et al. Novel delivery system enhances efficacy of antiretroviral therapy in animal model for HIV-1 encephalitis. J Cereb Blood Flow Metab 2007;27:1033-1042 (Pubitemid 46659034)
78. Webb K, Caldwell K, Tresco PA. Fibronectin immobilized by a novel surface treatment regulates fibroblast attachment and spreading. Crit Rev Biomed Eng 2000;28:203-208 (Pubitemid 30695064)
79. Lockman PR, Mumper RJ, Khan MA, et al. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm 2002;28:1-13 (Pubitemid 34279373)
80. Ojewole E, Mackraj I, Naidoo P, et al. Exploring the use of novel drug delivery systems for antiretroviral drugs. Eur J Pharm Biopharm 2008;697-710 •• This article reviews the potential of novel drug delivery systems for the future effective treatment of HIV/AIDS.
81. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev 2001;47:65-81 (Pubitemid 32209233)
82. Alyautdin RN, Tezikov EB, Ramge P, et al. Significant entry of tubocurarine into the brain of rats by adsorption to polysorbate 80-coated polybutylcyanoacrylate nanoparticles: an in situ brain perfusion study. J Microencapsul 1998;15:67-74 (Pubitemid 28031791)
83. Tosi G, Costantino L, Rivasi F, et al. Targeting the central nervous system: in vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. J Control Release 2007;122:1-9 (Pubitemid 47284547)
84. Kaur IP, Bhandari R, Bhandari S, et al. Potential of solid lipid nanoparticles in brain targeting. J Control Release 2008;127:97-109
85. Dechy-Cabaret O, Martin-Vaca B, Bourissou D. Controlled ring-opening polymerization of lactide and glycolide. Chem Rev 2004;104:6147-6176 (Pubitemid 40025736)
86. Yoo JY, Kim JM, Seo KS, et al. Characterization of degradation behavior for PLGA in various pH condition by simple liquid chromatography method. Biomed Mater Eng 2005;15:279-288
87. Zhang Z, Feng SS. The drug encapsulation efficiency, in vitro drug release, cellular uptake and cytotoxicity of paclitaxel-loaded poly(lactide)-tocopheryl polyethylene glycol succinate nanoparticles. Biomaterials 2006;27:4025-4033
88. Hanson LR, Frey WH. Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease. BMC Neurosci 2008;9(Suppl 3):S5
89. Tadayoni BM, Friden PM, Walus LR, et al. Synthesis, in vitro kinetics and in vivo studies on protein conjugates of AZT: evaluation as a transport system to increase brain delivery. Bioconjug Chem 1993;4:139-145
90. Temsamani J, Rousselle C, Rees AR, et al. Vector-mediated drug delivery to the brain. Expert Opin Biol Ther 2001;1:773-782
91. Hermanson GT. Bioconjugate Techniques. London: Academic Press, 1996
92. Lockman PR, Oyewumi MO, Koziara JM, et al. Brain uptake of thiamine-coated nanoparticles. J Control Release 2003;93:271-282
93. Mishra V, Mahor S, Rawat A, et al. Targeted brain delivery of AZT via transferrin anchored pegylated albumin nanoparticles. J Drug Target 2006;14:45-53
94. Dou H, Morehead J, Destache CJ, et al. Laboratory investigations for the morphologic, pharmacokinetic, and anti-retroviral properties of indinavir nanoparticles in human monocyte-derived macrophages. Virology 2007;358:148-158 (Pubitemid 46048870)
95. Dou H, Destache CJ, Morehead JR, et al. Development of a macrophage-based nanoparticle platform for antiretroviral drug delivery. Blood 2006;108:2827-2835 •• Proof-of-concept study describing the use of macrophages loaded with indinavir nanoparticles for targeting HIV. (Pubitemid 44777023)
96. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004;10:310-315
97. Richard JP, Melikov K, Vives E, et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J Biol Chem 2003;278:585-590 (Pubitemid 36043612)
98. Temsamani J, Vidal P. The use of cell-penetrating peptides for drug delivery. Drug Discov Today 2004;9:1012-1019 (Pubitemid 39574557)
99. Zheng L, Yang YD, Lu GC, et al. Extracellular HIV Tat and Tat cysteine rich peptide increase CCR5 expression in monocytes. J Zhejiang Univ Sci B 2005;6:668-672 (Pubitemid 41037820)
100. Vives E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997;272:16010-16017 (Pubitemid 27265584)
101. Derossi D, Calvet S, Trembleau A, et al. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996;271:18188-18193 (Pubitemid 26250811)
102. Schwarze SR, Ho A, Vocero-Akbani A, et al. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 1999;285:1569-1572 • Breakthrough study describing the potential of TAT-conjugation to facilitate delivery of macromolecules to the brain.
103. Peetla C, Rao KS, Labhasetwar V. Relevance of biophysical interactions with model membrane in predicting cellular uptake: study with TAT peptide-conjugated nanoparticles. Mol Pharm 2009 In press
104. Kravcik S, Gallicano K, Roth V, et al. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir. J Acquir Immune Defic Syndr 1999;21:371-375 (Pubitemid 29383998)
105. Sabatier JM, Vives E, Mabrouk K, et al. Evidence for neurotoxic activity of tat from human immunodeficiency virus type 1. J Virol 1991;65:961-967